Table 1 Demographic and clinical characteristics of persons who initiated treatment for RR or M/XDR TB according to pre-existing comorbidity status in Georgia, 2009–2017 (N = 1032).

From: HIV co-infection increases the risk of post-tuberculosis mortality among persons who initiated treatment for drug-resistant tuberculosis

Characteristics

Total

N = 1032

N (%)

HIV positivea

N (%) = 39 (3.8)

Hyperglycemiab

N (%) = 234 (22.7)

Diabetesb

N (%) = 115 (11.4)

HCV positivec

N (%) = 153 (14.7)

N (%)d

N (%)d

N (%)d

N (%)d

Age, median (IQR)

35 (26–49)

40 (35–47)

42.5 (32–54)

50 (41–59)

42 (34–50)

Male gender

753 (73.0)

33 (84.6)

189 (80.8)

92 (80.0)

148 (96.7)

Ethnicity, Georgian

942 (91.3)

33 (84.6)

212 (90.6)

104 (90.4)

142 (92.8)

BMI kg/m2, median (IQR)

20.8 (19.1–22.9)

21.2 (18.4–22.0)

21.6 (19.9–24.8)

23.6 (20.9–29.7)

21.1 (19.4–23.2)

Smear positive (n = 983)

655 (66.6)

13/36 (36.1)

173/228 (75.9)

95/113 (84.1)

98/144 (68.1)

Culture positive (n = 883)

876 (99.2)

37/37 (100.0)

199/201 (99.0)

99/99 (100.0)

128/129 (99.2)

RR TB

195 (18.9)

4 (10.3)

42 (18.0)

20 (17.4)

28 (18.3)

MDR/pre-XDR TB

761 (73.7)

32 (82.1)

170 (72.7)

85 (73.9)

118 (77.1)

XDR TB

76 (7.4)

3 (7.7)

22 (9.4)

10 (8.7)

7 (4.6)

Abnormal chest X-ray findings (n = 1014)

975 (96.2)

34/38 (89.5)

215/231 (93.1)

105/112 (93.8)

149/151 (98.7)

Cavitary disease

285 (27.6)

5 (12.8)

64 (27.4)

34 (29.6)

44 (28.8)

Infiltrate

755 (73.2)

22 (56.4)

169 (72.2)

84 (73.0)

113 (73.9)

Disseminated TB disease

251 (24.3)

10 (25.6)

60 (25.6)

60 (25.6)

45 (29.4)

History of internally displaced (n = 874)

36 (4.1)

2/33 (6.1)

5/207 (2.4)

2 (1.7)

6/118 (5.1)

Tobacco use (n = 591)

455 (44.1)

18/20 (90.0)

104/137 (75.9)

53/69 (76.8)

97/106 (91.5)

Excessive alcohol intake (n = 998)

59 (5.9)

1/37 (2.7)

16/227 (7.1)

6/114 (5.3)

16/145 (11.0)

Treatment outcome (n = 980)

 Completed/cured

655 (65.4)

10/36 (27.8)

157/231 (68.0)

76/113 (67.3)

73/142 (51.4)

 Poor treatment outcome

325 (33.2)

26/36 (72.2)

74/231 (32.0)

37/113 (32.7)

69/142 (48.6)

  Failed the treatment

44/325 (13.5)

5/26 (19.2)

13/74 (17.6)

7/37 (18.9)

10/69 (14.5)

  Lost to follow-up

247/325 (76.0)

14/26 (53.9)

58/74 (78.4)

27/37 (73.0)

53/69 (76.8)

  Died during TB treatment

34/325 (10.5)

7/26 (26.9)

3/74 (4.1)

3/37 (8.1)

6/69 (8.7)

Return to caree

95 (9.2)

6 (15.4)

32 (13.7)

17 (14.8)

18 (11.8)

Survival status

     

Alive

911 (88.3)

23 (59.0)

204 (87.2)

98 (85.2)

129 (84.3)

Mortality during treatment

34 (3.3)

7 (18.0)

3 (1.3)

3 (2.6)

6 (3.9)

Mortality post-TB treatment

87 (8.4)

9 (23.0)

27 (11.5)

14 (12.2)

18 (11.8)

  1. BMI: body mass index; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IQR: interquartile range; MDR: multidrug resistant; pre-XDR: pre-extensively drug resistant; RR: rifampicin resistant; TB: tuberculosis; XDR: extensively drug-resistant.
  2. aThere were 96 individuals with missing/unknown HIV co-infection status.
  3. bThere were 220 individuals with missing/unknown prediabetes/diabetes status.
  4. cThere were 282 individuals with missing/unknown HCV co-infection status.
  5. dDenominators were shown for rows where missing values (on either demographic/clinical characteristics or comorbidity status) were observed.
  6. eReturn to care was defined if individuals re-entered the online surveillance system with a new treatment ID (i.e., relapse, re-infection, or re-treatment after treatment failure.
Back to article page